Given stakeholder feedback received following the publication of our April 2017 report on trends in opioid-related deaths across Ontario, we have generated a supplemental report outlining some of the trends and characteristics of opioid-related deaths, stratified by sex.
This study examines the use of first-line alcohol use disorder (AUD) medications (naltrexone and acamprosate) among public drug plan beneficiaries in the year following an AUD diagnosis.
To inform policy recommendations on the use of immunotherapy in Ontario, the ODPRN performed a rapid umbrella review of existing systematic reviews that assessed the benefits and harms of allergen immunotherapy for treatment of allergic rhinitis or asthma.
Provincial governments across Canada have implemented blood glucose test strip (BGTS) quantity limits to encourage proper testing practices for optimal patient outcomes. The ODPRN has developed a provincial list of implementation details for each province as of May 2017.